Advisor Group Inc. held its stake in shares of Accelerate Diagnostics, Inc. (NASDAQ:AXDX) during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 11,550 shares of the medical research company’s stock at the end of the 2nd quarter. Advisor Group Inc.’s holdings in Accelerate Diagnostics were worth $316,000 as of its most recent SEC filing.

Several other institutional investors have also made changes to their positions in the stock. Vanguard Group Inc. boosted its position in shares of Accelerate Diagnostics by 6.7% during the 2nd quarter. Vanguard Group Inc. now owns 1,237,174 shares of the medical research company’s stock valued at $33,837,000 after purchasing an additional 77,753 shares in the last quarter. Blair William & Co. IL boosted its position in shares of Accelerate Diagnostics by 15.1% during the 2nd quarter. Blair William & Co. IL now owns 787,483 shares of the medical research company’s stock valued at $21,538,000 after purchasing an additional 103,276 shares in the last quarter. Nuveen Asset Management LLC boosted its position in shares of Accelerate Diagnostics by 1.3% during the 1st quarter. Nuveen Asset Management LLC now owns 736,997 shares of the medical research company’s stock valued at $17,835,000 after purchasing an additional 9,568 shares in the last quarter. FMR LLC boosted its position in shares of Accelerate Diagnostics by 40.0% during the 2nd quarter. FMR LLC now owns 420,072 shares of the medical research company’s stock valued at $11,489,000 after purchasing an additional 120,072 shares in the last quarter. Finally, Credit Suisse AG boosted its position in shares of Accelerate Diagnostics by 138.4% during the 1st quarter. Credit Suisse AG now owns 413,131 shares of the medical research company’s stock valued at $9,998,000 after purchasing an additional 239,803 shares in the last quarter. Institutional investors own 44.43% of the company’s stock.

In other Accelerate Diagnostics news, insider Lawrence Mehren sold 223,215 shares of Accelerate Diagnostics stock in a transaction that occurred on Thursday, August 17th. The stock was sold at an average price of $22.40, for a total transaction of $5,000,016.00. Following the sale, the insider now directly owns 762,381 shares of the company’s stock, valued at approximately $17,077,334.40. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Jack W. Schuler acquired 23,400 shares of the business’s stock in a transaction on Monday, August 14th. The shares were purchased at an average cost of $21.35 per share, for a total transaction of $499,590.00. The disclosure for this purchase can be found here. Over the last ninety days, insiders have acquired 161,600 shares of company stock worth $3,461,560. Insiders own 51.40% of the company’s stock.

Accelerate Diagnostics, Inc. (AXDX) opened at 19.80 on Friday. The firm has a 50-day moving average price of $22.55 and a 200 day moving average price of $25.47. Accelerate Diagnostics, Inc. has a one year low of $19.20 and a one year high of $30.45. The company’s market cap is $1.09 billion.

Accelerate Diagnostics (NASDAQ:AXDX) last posted its quarterly earnings data on Thursday, August 3rd. The medical research company reported ($0.31) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.30) by ($0.01). The firm had revenue of $0.70 million for the quarter, compared to the consensus estimate of $1.40 million. Accelerate Diagnostics had a negative net margin of 5,062.48% and a negative return on equity of 67.44%. Equities analysts expect that Accelerate Diagnostics, Inc. will post ($1.20) earnings per share for the current fiscal year.

Several equities research analysts recently commented on AXDX shares. BidaskClub lowered Accelerate Diagnostics from a “buy” rating to a “hold” rating in a research report on Saturday, July 1st. BTIG Research reiterated a “buy” rating and issued a $34.00 price target on shares of Accelerate Diagnostics in a report on Wednesday, July 12th. Zacks Investment Research lowered Accelerate Diagnostics from a “hold” rating to a “sell” rating in a report on Tuesday, October 3rd. Finally, ValuEngine lowered Accelerate Diagnostics from a “hold” rating to a “sell” rating in a report on Friday, August 11th. Three analysts have rated the stock with a sell rating and two have assigned a buy rating to the company’s stock. Accelerate Diagnostics currently has a consensus rating of “Hold” and a consensus price target of $33.00.

WARNING: This piece of content was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of US and international copyright law. The correct version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/10/13/accelerate-diagnostics-inc-axdx-position-maintained-by-advisor-group-inc.html.

Accelerate Diagnostics Profile

Accelerate Diagnostics, Inc is an in vitro diagnostics company engaged in providing solutions that develop patient outcomes through the diagnosis of serious infections. The Company’s in vitro diagnostic platform, the Accelerate Pheno system utilizes genotypic technology to identify (ID), infectious pathogens and phenotypic technology to conduct antibiotic susceptibility testing (AST), which determines whether live bacterial or fungal cells are resistant or susceptible to a particular antibiotic.

Want to see what other hedge funds are holding AXDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Accelerate Diagnostics, Inc. (NASDAQ:AXDX).

Institutional Ownership by Quarter for Accelerate Diagnostics (NASDAQ:AXDX)

Receive News & Stock Ratings for Accelerate Diagnostics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accelerate Diagnostics Inc. and related stocks with our FREE daily email newsletter.